Last day of trading in warrants of series TO 1 is November 14, 2022
Oslo, Norway, November 10, 2022 – November 14, 2022, is the last day of trading in warrants of series TO 1, which were issued in connection with Genetic Analysis AS’s (“GA” or the “Company”) IPO of units in September/October 2021. The exercise period runs until November 16, 2022. Holders of warrants of series TO 1 are entitled to subscribe for one (1) new share in GA at a price of NOK 9.30 per share. The Company's share price is currently substantially lower than the subscription price and thus something that warrant holders should be aware of when considering possible subscription of shares.
General terms and conditions and information concerning the warrants of series TO 1:
- Exercise period: Subscription of new shares, with support of warrants of series TO 1, take place during the period November 2, 2022, and November 16, 2022.
- Last day of trading in warrants of series TO 1: November 14, 2022.
- Subscription notification: Should be made directly to the Company by completing, signing, and returning the document to the Company no later than November 16, 2022. The document is available on the Company’s website https://www.genetic-analysis.com/ipo-2021/. The subscription amount shall be paid in Norwegian kroner (NOK) to the Company's bank account within two days.
- Subscription price: Each warrant of series TO 1 entitles the holder to subscribe for one (1) new share in GA at a price of NOK 9.30.
- Issue volume: There are 4,620,000 outstanding warrants of series TO 1 which, if fully exercised, could provide the Company with approximately NOK 43 million before deduction of transaction related costs.
- Ticker and ISIN code: Warrants of series TO 1 are traded on Spotlight Stock Market under the ticker GEAN TO 1 and the ISIN code NO0011054223.
- Communication of outcome: Around November 21, 2022.
- Other: No interim shares will be issued.
Advisors and issuing agent:
Sedermera Corporate Finance AB is the Swedish financial advisor to GA in connection with the exercise of warrants of series TO 1. The law firm Wiersholm AS is acting as legal advisor and DNB Bank ASA is acting as issuing agent. Shark Communication AB assists the Company with advice regarding communication.
For more information about warrants of series TO 1, please contact:
Eilert Aamodt, CFO
E-mail: ea@genetic-analysis.com
Website: www.genetic-analysis.com
For more information about GA, please contact:
Ronny Hermansen, CEO
E-mail: rh@genetic-analysis.com
This is a translation of the Swedish original. If there is any inconsistency between the English and Swedish versions, the Swedish version shall prevail.
About Genetic Analysis:
Genetic Analysis AS (GA) is a science-based diagnostic company and pioneer in the human microbiome field with more than 10 years of expertise in research and product development. The unique GA-map® platform is based on a pre-determined multiplex targets approach specialized for simultaneous analysis of a large number of bacteria in one reaction. The test results are generated by utilizing the clinically validated cutting edge GA-map® software algorithm. This enables immediate results without the need for further bioinformatics work. GA’s vision is to become the leading company for standardized gut microbiota testing worldwide, and GA is committed to help unlocking and restoring the human microbiome through its state-of-the-art technology. GA employs a team of highly qualified employees with scientific backgrounds and competence in bioinformatics, molecular biology, and bioengineering. www.genetic-analysis.com